Teva Pharmaceutical Industries Limited (TEVA) Lowered to Strong Sell at BidaskClub

BidaskClub downgraded shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA) from a sell rating to a strong sell rating in a research note issued to investors on Friday morning.

Several other research analysts have also weighed in on the stock. Piper Jaffray Companies set a $23.00 target price on shares of Teva Pharmaceutical Industries Limited and gave the stock a hold rating in a research note on Friday, October 6th. Wells Fargo & Company set a $20.00 target price on shares of Teva Pharmaceutical Industries Limited and gave the stock a hold rating in a research note on Wednesday, October 4th. Morgan Stanley set a $15.00 target price on shares of Teva Pharmaceutical Industries Limited and gave the stock an underweight rating in a research note on Thursday, October 5th. Cowen and Company reaffirmed a market perform rating and set a $18.00 target price (down previously from $30.00) on shares of Teva Pharmaceutical Industries Limited in a research note on Wednesday, October 4th. Finally, Maxim Group reaffirmed a hold rating on shares of Teva Pharmaceutical Industries Limited in a research note on Wednesday, October 4th. Five equities research analysts have rated the stock with a sell rating, eighteen have assigned a hold rating, six have assigned a buy rating and one has given a strong buy rating to the company’s stock. Teva Pharmaceutical Industries Limited has a consensus rating of Hold and a consensus price target of $27.63.

Teva Pharmaceutical Industries Limited (TEVA) traded down 1.12% during midday trading on Friday, hitting $14.98. 27,439,869 shares of the stock traded hands. The stock has a 50-day moving average of $16.72 and a 200 day moving average of $26.15. The firm’s market cap is $15.22 billion. Teva Pharmaceutical Industries Limited has a 52-week low of $14.30 and a 52-week high of $44.42.

Teva Pharmaceutical Industries Limited (NYSE:TEVA) last announced its earnings results on Thursday, August 3rd. The company reported $0.99 earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of $1.06 by ($0.07). The company had revenue of $5.69 billion for the quarter, compared to analysts’ expectations of $5.72 billion. Teva Pharmaceutical Industries Limited had a positive return on equity of 15.96% and a negative net margin of 25.18%. The company’s quarterly revenue was up 12.9% compared to the same quarter last year. During the same period last year, the business earned $1.25 EPS. Equities analysts forecast that Teva Pharmaceutical Industries Limited will post $4.24 EPS for the current year.

ILLEGAL ACTIVITY NOTICE: This piece of content was published by The Ledger Gazette and is the sole property of of The Ledger Gazette. If you are accessing this piece of content on another publication, it was illegally copied and reposted in violation of United States and international copyright laws. The correct version of this piece of content can be read at https://ledgergazette.com/2017/10/14/teva-pharmaceutical-industries-limited-teva-lowered-to-strong-sell-at-bidaskclub.html.

The business also recently disclosed a quarterly dividend, which was paid on Thursday, September 14th. Shareholders of record on Tuesday, August 29th were issued a dividend of $0.085 per share. The ex-dividend date was Friday, August 25th. This represents a $0.34 dividend on an annualized basis and a yield of 2.27%. Teva Pharmaceutical Industries Limited’s payout ratio is currently -15.36%.

A number of hedge funds have recently added to or reduced their stakes in the business. Sii Investments Inc. WI raised its holdings in Teva Pharmaceutical Industries Limited by 0.4% during the first quarter. Sii Investments Inc. WI now owns 6,739 shares of the company’s stock worth $214,000 after purchasing an additional 25 shares in the last quarter. Salem Investment Counselors Inc. raised its holdings in Teva Pharmaceutical Industries Limited by 0.4% during the first quarter. Salem Investment Counselors Inc. now owns 8,332 shares of the company’s stock worth $267,000 after purchasing an additional 32 shares in the last quarter. Security National Bank of Sioux City Iowa IA raised its holdings in Teva Pharmaceutical Industries Limited by 0.4% during the second quarter. Security National Bank of Sioux City Iowa IA now owns 21,788 shares of the company’s stock worth $724,000 after purchasing an additional 87 shares in the last quarter. Bronfman E.L. Rothschild L.P. raised its holdings in Teva Pharmaceutical Industries Limited by 2.6% during the second quarter. Bronfman E.L. Rothschild L.P. now owns 3,711 shares of the company’s stock worth $123,000 after purchasing an additional 94 shares in the last quarter. Finally, Sterling Investment Advisors Ltd. raised its holdings in Teva Pharmaceutical Industries Limited by 2.6% during the first quarter. Ste

Several other research analysts have also weighed in on the stock. Piper Jaffray Companies set a $23.00 target price on shares of Teva Pharmaceutical Industries Limited and gave the stock a hold rating in a research note on Friday, October 6th. Wells Fargo & Company set a $20.00 target price on shares of Teva Pharmaceutical Industries Limited and gave the stock a hold rating in a research note on Wednesday, October 4th. Morgan Stanley set a $15.00 target price on shares of Teva Pharmaceutical Industries Limited and gave the stock an underweight rating in a research note on Thursday, October 5th. Cowen and Company reaffirmed a market perform rating and set a $18.00 target price (down previously from $30.00) on shares of Teva Pharmaceutical Industries Limited in a research note on Wednesday, October 4th. Finally, Maxim Group reaffirmed a hold rating on shares of Teva Pharmaceutical Industries Limited in a research note on Wednesday, October 4th. Five equities research analysts have rated the stock with a sell rating, eighteen have assigned a hold rating, six have assigned a buy rating and one has given a strong buy rating to the company’s stock. Teva Pharmaceutical Industries Limited has a consensus rating of Hold and a consensus price target of $27.63.

Teva Pharmaceutical Industries Limited (TEVA) traded down 1.12% during midday trading on Friday, hitting $14.98. 27,439,869 shares of the stock traded hands. The stock has a 50-day moving average of $16.72 and a 200 day moving average of $26.15. The firm’s market cap is $15.22 billion. Teva Pharmaceutical Industries Limited has a 52-week low of $14.30 and a 52-week high of $44.42.

Teva Pharmaceutical Industries Limited (NYSE:TEVA) last announced its earnings results on Thursday, August 3rd. The company reported $0.99 earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of $1.06 by ($0.07). The company had revenue of $5.69 billion for the quarter, compared to analysts’ expectations of $5.72 billion. Teva Pharmaceutical Industries Limited had a positive return on equity of 15.96% and a negative net margin of 25.18%. The company’s quarterly revenue was up 12.9% compared to the same quarter last year. During the same period last year, the business earned $1.25 EPS. Equities analysts forecast that Teva Pharmaceutical Industries Limited will post $4.24 EPS for the current year.

ILLEGAL ACTIVITY NOTICE: This piece of content was published by The Ledger Gazette and is the sole property of of The Ledger Gazette. If you are accessing this piece of content on another publication, it was illegally copied and reposted in violation of United States and international copyright laws. The correct version of this piece of content can be read at https://ledgergazette.com/2017/10/14/teva-pharmaceutical-industries-limited-teva-lowered-to-strong-sell-at-bidaskclub.html.

The business also recently disclosed a quarterly dividend, which was paid on Thursday, September 14th. Shareholders of record on Tuesday, August 29th were issued a dividend of $0.085 per share. The ex-dividend date was Friday, August 25th. This represents a $0.34 dividend on an annualized basis and a yield of 2.27%. Teva Pharmaceutical Industries Limited’s payout ratio is currently -15.36%.

A number of hedge funds have recently added to or reduced their stakes in the business. Sii Investments Inc. WI raised its holdings in Teva Pharmaceutical Industries Limited by 0.4% during the first quarter. Sii Investments Inc. WI now owns 6,739 shares of the company’s stock worth $214,000 after purchasing an additional 25 shares in the last quarter. Salem Investment Counselors Inc. raised its holdings in Teva Pharmaceutical Industries Limited by 0.4% during the first quarter. Salem Investment Counselors Inc. now owns 8,332 shares of the company’s stock worth $267,000 after purchasing an additional 32 shares in the last quarter. Security National Bank of Sioux City Iowa IA raised its holdings in Teva Pharmaceutical Industries Limited by 0.4% during the second quarter. Security National Bank of Sioux City Iowa IA now owns 21,788 shares of the company’s stock worth $724,000 after purchasing an additional 87 shares in the last quarter. Bronfman E.L. Rothschild L.P. raised its holdings in Teva Pharmaceutical Industries Limited by 2.6% during the second quarter. Bronfman E.L. Rothschild L.P. now owns 3,711 shares of the company’s stock worth $123,000 after purchasing an additional 94 shares in the last quarter. Finally, Sterling Investment Advisors Ltd. raised its holdings in Teva Pharmaceutical Industries Limited by 2.6% during the first quarter. Sterling Investment Advisors Ltd. now owns 3,900 shares of the company’s stock worth $125,000 after purchasing an additional 100 shares in the last quarter. 56.75% of the stock is currently owned by institutional investors.

About Teva Pharmaceutical Industries Limited

Teva Pharmaceutical Industries Limited is a pharmaceutical company. The Company is engaged in developing, producing and marketing generic medicines and a portfolio of specialty medicines. The Company operates through two segments: Generic medicines and Specialty medicines. The Company develops, manufactures and sells generic medicines in a range of dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments and creams.

Analyst Recommendations for Teva Pharmaceutical Industries Limited (NYSE:TEVA)

Receive News & Ratings for Teva Pharmaceutical Industries Limited Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teva Pharmaceutical Industries Limited and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply